Organon & Co. (NYSE:OGN) Shares Bought by LSV Asset Management

LSV Asset Management grew its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,525,076 shares of the company's stock after buying an additional 30,557 shares during the period. LSV Asset Management owned 2.92% of Organon & Co. worth $112,274,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OGN. Pacer Advisors Inc. raised its holdings in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after acquiring an additional 11,140,388 shares during the period. Norges Bank bought a new position in shares of Organon & Co. during the 4th quarter valued at about $25,258,000. Magnetar Financial LLC increased its holdings in shares of Organon & Co. by 560.2% in the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company's stock worth $25,878,000 after purchasing an additional 1,471,731 shares during the last quarter. Invesco Ltd. increased its stake in Organon & Co. by 44.6% in the 4th quarter. Invesco Ltd. now owns 2,034,780 shares of the company's stock worth $30,359,000 after acquiring an additional 627,944 shares during the last quarter. Finally, Brandywine Global Investment Management LLC grew its holdings in shares of Organon & Co. by 34.6% in the fourth quarter. Brandywine Global Investment Management LLC now owns 2,029,923 shares of the company's stock valued at $30,286,000 after purchasing an additional 521,847 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Remove Ads

Organon & Co. Trading Down 2.1 %

Shares of NYSE OGN traded down $0.24 during trading hours on Tuesday, reaching $11.07. The stock had a trading volume of 3,124,349 shares, compared to its average volume of 2,655,209. The business's fifty day moving average price is $14.56 and its two-hundred day moving average price is $15.59. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of 3.32, a P/E/G ratio of 0.90 and a beta of 0.73. Organon & Co. has a 52-week low of $10.94 and a 52-week high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.12%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s dividend payout ratio is currently 33.63%.

Wall Street Analysts Forecast Growth

OGN has been the topic of a number of research reports. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Morgan Stanley dropped their target price on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. Finally, Barclays dropped their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Organon & Co. presently has a consensus rating of "Hold" and a consensus price target of $20.60.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.